205 related articles for article (PubMed ID: 30098272)
1. A multicenter, randomized, single-blind trial comparing the efficacy of viable cryopreserved placental membrane to human fibroblast-derived dermal substitute for the treatment of chronic diabetic foot ulcers.
Ananian CE; Dhillon YS; Van Gils CC; Lindsey DC; Otto RJ; Dove CR; Pierce JT; Saunders MC
Wound Repair Regen; 2018 May; 26(3):274-283. PubMed ID: 30098272
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of a human fibroblast-derived dermal substitute and a viable cryopreserved placental membrane for the treatment of diabetic foot ulcers.
Sabolinski ML; Capotorto JV
J Comp Eff Res; 2019 Oct; 8(14):1229-1238. PubMed ID: 31407588
[No Abstract] [Full Text] [Related]
3. Effectiveness of viable cryopreserved placental membranes for management of diabetic foot ulcers in a real world setting.
Raspovic KM; Wukich DK; Naiman DQ; Lavery LA; Kirsner RS; Kim PJ; Steinberg JS; Attinger CE; Danilkovitch A
Wound Repair Regen; 2018 Mar; 26(2):213-220. PubMed ID: 29683538
[TBL] [Abstract][Full Text] [Related]
4. Cryopreserved Placental Membranes Containing Viable Cells Result in High Closure Rate of Nonhealing Upper and Lower Extremity Wounds of Non-Diabetic and Non-Venous Pathophysiology.
Johnson EL; Saunders M; Thote T; Danilkovitch A
Wounds; 2021 Feb; 33(2):34-40. PubMed ID: 33591930
[TBL] [Abstract][Full Text] [Related]
5. A Prospective, Single-center, Open-label Case Series Evaluating the Clinical Outcomes of Lyopreserved Placental Membrane Containing Viable Cells in the Treatment of Chronic Wounds.
Reyzelman AM; Vartivarian M; Danilkovitch A; Saunders MC
Wounds; 2019 Apr; 31(4):97-102. PubMed ID: 30924793
[TBL] [Abstract][Full Text] [Related]
6. A prospective, multicenter, randomized, controlled clinical trial comparing a bioengineered skin substitute to a human skin allograft.
Sanders L; Landsman AS; Landsman A; Keller N; Cook J; Cook E; Hopson M
Ostomy Wound Manage; 2014 Sep; 60(9):26-38. PubMed ID: 25211605
[TBL] [Abstract][Full Text] [Related]
7. Wound closure in patients with DFU: a cost-effectiveness analysis of two cellular/tissue-derived products.
Gilligan AM; Waycaster CR; Landsman AL
J Wound Care; 2015 Mar; 24(3):149-56. PubMed ID: 25764960
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Wound Closure Rates Using a Human Fibroblast-derived Dermal Substitute Versus a Fetal Bovine Collagen Dressing: A Retrospective Study.
Fitzgerald RH; Sabolinski ML; Skornicki M
Wound Manag Prev; 2019 Sep; 65(9):26-34. PubMed ID: 31702990
[TBL] [Abstract][Full Text] [Related]
9. Stage IV Perineal Pressure Ulcers in Immobile Patients Treated With Surgical Flap Closure Augmented With Cryopreserved Placental Membrane Containing Viable Cells.
Golla D; Kurtz Phelan DH
Wounds; 2019 Jan; 31(1):15-18. PubMed ID: 30620708
[TBL] [Abstract][Full Text] [Related]
10. Surgical Application of Viable Cryopreserved Placental Membrane for the Treatment of Chronic Wounds in 12 High-risk Patients.
D'Costa WF; Kurtz Phelan DH
Wounds; 2018 Nov; 30(11):324-328. PubMed ID: 30418161
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic Skin Substitutes Versus Human Placental Membrane Products in the Management of Diabetic Foot Ulcers: A Narrative Comparative Evaluation of the Literature.
Luck J; Rodi T; Geierlehner A; Mosahebi A
Int J Low Extrem Wounds; 2019 Mar; 18(1):10-22. PubMed ID: 30663450
[TBL] [Abstract][Full Text] [Related]
12. Viable intact cryopreserved human placental membrane for a non-surgical approach to closure in complex wounds.
Suzuki K; Michael G; Tamire Y
J Wound Care; 2016 Oct; 25(Sup10):S25-S31. PubMed ID: 27681807
[TBL] [Abstract][Full Text] [Related]
13. Open-label Extension Phase of a Chronic Diabetic Foot Ulcer Multicenter, Controlled, Randomized Clinical Trial Using Cryopreserved Placental Membrane.
Lavery L; Fulmer J; Shebetka KA; Regulski M; Vayser D; Fried D; Kashefsky H; Owings TM; Nadarajah J; Hesp Z
Wounds; 2018 Sep; 30(9):283-289. PubMed ID: 30256747
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness analysis for commonly used human cell and tissue products in the management of diabetic foot ulcers.
Nherera LM; Banerjee J
Health Sci Rep; 2024 Mar; 7(3):e1991. PubMed ID: 38524772
[TBL] [Abstract][Full Text] [Related]
15. Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent: a new paradigm in wound healing.
Brem H; Balledux J; Bloom T; Kerstein MD; Hollier L
Arch Surg; 2000 Jun; 135(6):627-34. PubMed ID: 10843357
[TBL] [Abstract][Full Text] [Related]
16. Human fibroblast-derived dermal substitute: results from a treatment investigational device exemption (TIDE) study in diabetic foot ulcers.
Warriner RA; Cardinal M;
Adv Skin Wound Care; 2011 Jul; 24(7):306-11. PubMed ID: 21685733
[TBL] [Abstract][Full Text] [Related]
17. The Comparative Effectiveness of a Human Fibroblast Dermal Substitute versus a Dehydrated Human Amnion/Chorion Membrane Allograft for the Treatment of Diabetic Foot Ulcers in a Real-world Setting.
Kraus I; Sabolinski ML; Skornicki M; Parsons NB
Wounds; 2017 May; 29(5):125-132. PubMed ID: 28570252
[TBL] [Abstract][Full Text] [Related]
18. Poorly designed research does not help clarify the role of hyperbaric oxygen in the treatment of chronic diabetic foot ulcers.
Mutluoglu M; Uzun G; Bennett M; Germonpré P; Smart D; Mathieu D
Diving Hyperb Med; 2016 Sep; 46(3):133-134. PubMed ID: 27723012
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial.
Marston WA; Hanft J; Norwood P; Pollak R;
Diabetes Care; 2003 Jun; 26(6):1701-5. PubMed ID: 12766097
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of tissue engineering products for the management of neuropathic diabetic foot ulcers: an interim analysis.
Frykberg RG; Cazzell SM; Arroyo-Rivera J; Tallis A; Reyzelman AM; Saba F; Warren L; Stouch BC; Gilbert TW
J Wound Care; 2016 Jul; 25(Sup7):S18-S25. PubMed ID: 29027848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
